DALLAS, March 11, 2010 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Exact Sciences Corp. (Nasdaq:EXAS). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.investorsoup.com/lp/EXAS
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup">www.twitter.com/investorsoup
Exact Sciences Corp. (EXAS) develops deoxyribonucleic acid (DNA)-based technologies for use in the detection of cancer. The Company has selected colorectal cancer as the first application of its technologies. The Company has licensed certain of its technologies, on an exclusive basis through December 2010, to Laboratory Corporation of America Holdings (LabCorp). LabCorp developed and commercially offered PreGen-Plus, its first generation non-invasive stool-based DNA colorectal cancer screening service for the average-risk population.
Message Board Search for EXAS: http://www.boardcentral.com/boards/EXAS
In the report, the analyst notes:
"EXAS reported total revenues of $1.2 million for the fourth quarter of 2009, compared to total revenues of ($109,000) during the same period of 2008. Fourth-quarter 2009 total revenues increased due to the quarterly non-cash allocation that resulted from a 2009 intellectual property license transaction. Total revenues for the year ended Dec. 31, 2009, were $4.8 million, compared to total revenues of ($867,000) for the prior year.
"By simplifying the routine screening process, stool-based DNA screening directly addresses patient non-compliance issues. As a result, more patients may be safely screened without the discomfort and inconvenience associated with invasive procedures. Greater compliance, in turn, may lead to earlier detection and potentially the prevention of colorectal cancer. Colorectal cancer is the second-leading cause of cancer deaths, according to the American Cancer Society. Almost 150,000 new cases of colorectal cancer are diagnosed and approximately 50,000 people die from the disease every year."
To read the entire report visit: http://www.investorsoup.com/lp/EXAS
See what investors say about EXAS at penny stock forum
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit www.InvestorSoup.com/">http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither InvestorSoup nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.